COLIRIOBCN070660

DRUG2 trials

Sponsors

Bcn Peptides S.A., BCN Peptides

Conditions

Diabetic Retinopathy

Phase 2

Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy

CompletedNCT01726075

BCN PeptidesDiabetic Retinopathy

Start: 2013-02-28End: 2015-11-30Updated: 2016-01-12

A multicentric, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of COLIRIOBCN070660 administered topically in patients with moderately severe to severe non-proliferative diabetic retinopathy

RecruitingCTIS2023-505791-30-01

Bcn Peptides S.A.Diabetic Retinopathy

Start: 2024-04-17Target: 100Updated: 2025-05-30

Related Papers

Functional and Structural Findings of Neurodegeneration in Early Stages of Diabetic Retinopathy: Cross-sectional Analyses of Baseline Data of the EUROCONDOR Project

Diabetes2017-06-29151 citations